3rd Annual Atlanta Precision Oncology Symposium

Videos
12:36

3rd Annual Atlanta Precision Oncology Symposium

Genotype-Directed Therapy for Advanced NSCLC: Overview of Targeted Therapy Efficacy Data for RET & MET Mutations

FEATURING Hossein Borghaei
  • 542 views
  • March 7, 2021
26:48

3rd Annual Atlanta Precision Oncology Symposium

Targeted Therapies for Advanced Urothelial Cancer: Erdafitinib for Patients With FGFR3 Alterations, 3L Enfortumab Vedotin and IMMU-132

FEATURING Daniel Petrylak
  • 148 views
  • February 14, 2021
13:52

3rd Annual Atlanta Precision Oncology Symposium

Targeted Therapy for Advanced NSCLC: Efficacy Analysis of RET, KRAS, HER2 & BRAF Targeting Agents

FEATURING Hossein Borghaei
  • 38 views
  • March 7, 2021
25:48

3rd Annual Atlanta Precision Oncology Symposium

2021 Expert Discussion on GU Cancers: Should We Use Olaparib Before or After Chemo for BRCA Patients? How to Deal With Pancreatic Mets? Is It Better to Start With Chemo or Oral Agents for mCRPC?

FEATURING Emmanuel Antonarakis, Daniel Petrylak, Tian Zhang
  • 239 views
  • February 14, 2021
  • 2
26:48

3rd Annual Atlanta Precision Oncology Symposium

Treatment of DNA Repair-Deficient Advanced Prostate Cancer

FEATURING Emmanuel Antonarakis
  • 244 views
  • February 14, 2021
  • 2
26:42

3rd Annual Atlanta Precision Oncology Symposium

2021 Expert Discussion on Advanced NSCLC: Is Osimertinib a Good Sequencing Choice for EGFRm Patients? When to Discontinue TKI Therapy? How to Approach Patients on Maintenance?

FEATURING Edward Garon, Nasser Hanna, Hossein Borghaei, Jesse Kirkpatrick
  • 393 views
  • February 14, 2021
  • 2
23:13

3rd Annual Atlanta Precision Oncology Symposium

Early Detection of Lung Cancer: Molecular Enrichment Strategy

FEATURING Jesse Kirkpatrick
  • 101 views
  • February 14, 2021
  • 2
18:36

3rd Annual Atlanta Precision Oncology Symposium

Selecting Systemic First-Line Treatment in Stage IV NSCLC Without Driver Mutations: ASCO/CCO Updated Guidelines

FEATURING Nasser Hanna
  • 327 views
  • February 14, 2021
  • 3
20:20

3rd Annual Atlanta Precision Oncology Symposium

2021 Expert Discussion on BC: How to Preoperatively Manage TNBC? How Does Tala Compare to Chemo? Are CDK4/6i Beneficial in ER+ Disease? What Is the 2L Sequencing Procedure?

FEATURING Ingrid Mayer, Jennifer Litton, Ruth O’Regan
  • 38 views
  • February 12, 2021
32:45

3rd Annual Atlanta Precision Oncology Symposium

2021 Updates on Systemic Therapy for TNBC: Why Should We Choose Neoadjuvant vs. Adjuvant? How Beneficial Is Antracycline-Taxane Chemo? When Should Carboplatin & Immune CPIs Be Used?

FEATURING Ruth O’Regan
  • 46 views
  • February 12, 2021
06:49

3rd Annual Atlanta Precision Oncology Symposium

IO for mTNBC: Overview of the Efficacy Data

FEATURING Jennifer Litton
  • 352 views
  • February 12, 2021
13:30

3rd Annual Atlanta Precision Oncology Symposium

ADCs & Targeted Therapies for Advanced TNBC: Can Sacituzumab Govitecan Improve PFS? Should We Use Tala vs. Chemo for BRCA1/2 Patients? Is Olaparib Mono a New SoC?

FEATURING Jennifer Litton
  • 96 views
  • February 12, 2021
  • 1
09:52

3rd Annual Atlanta Precision Oncology Symposium

EGFR+ Advanced NSCLC: Should 1L Therapy Include an EGFR Inhibitor Regardless of PD-L1 Expression?

FEATURING Edward Garon
  • 99 views
  • February 9, 2021
15:01

3rd Annual Atlanta Precision Oncology Symposium

EGFR+ Advanced NSCLC: Efficacy Data of TKIs in Combination vs. Alone, RELAY Overview of Ramucirumab + Erlotinib

FEATURING Edward Garon
  • 141 views
  • February 9, 2021
  • 1
05:55

3rd Annual Atlanta Precision Oncology Symposium

Sequence Algorithm for HER2+ Breast Cancer: Does Neratinib + Cape Have Superior PFS Compared to Lapatinib + Cape?

FEATURING Ingrid Mayer
  • 31 views
  • February 9, 2021
05:03

3rd Annual Atlanta Precision Oncology Symposium

CNS Metastases in HER2+ MBC: PFS Data on the Addition of Tucatinib to Capecitabine and Trastuzumab

FEATURING Ingrid Mayer
  • 605 views
  • February 9, 2021
  • 1
17:47

3rd Annual Atlanta Precision Oncology Symposium

HER2+ MBC Sequencing Algorithm: Surveying the Data for Antibody-Drug Conjugates

FEATURING Ingrid Mayer
  • 37 views
  • February 9, 2021
14:04

3rd Annual Atlanta Precision Oncology Symposium

[PRIVATE] Targeted Therapies for mRCC: Surveying Efficacy Data for IO/IO and VEGF/IO Combinations

FEATURING Tian Zhang
  • 15 views
  • June 11, 2021
17:05

3rd Annual Atlanta Precision Oncology Symposium

[PRIVATE] Targeted Therapies for mRCC: Assessing IMDC Risk Criteria and Special Populations, TFS as a New Endpoint

FEATURING Tian Zhang
  • 11 views
  • June 11, 2021
08:45

3rd Annual Atlanta Precision Oncology Symposium

Targeting Genetic Mutations in mNSCLC: Clinical Data Overview of RET, MET Exon 14, and KRAS G12C

FEATURING Holli Dilks
  • 284 views
  • February 9, 2021